EMPOWERING HEALTHCARE WITH DATA
01 / ANALYSIS
Biome AI is at the forefront of accelerating microbiome research. We use high-throughput DNA sequencing and machine learning technologies to decipher interconnections between the microbiome and the human body. Microbiome research has become a highly active and exciting area of science with large promises and even larger knowledge gaps awaiting to be filled.
02 / DISCOVERY
The microbiome is the community of microorganisms in the human body. It has been linked to weight gain/loss, obesity, depression, cancer, auto-immune diseases (Multiple Sclerosis, IBS, Arthritis, Celiac & Chrones disease) and cardiovascular health. These conditions impact lives and cost taxpayers and the healthcare industry billions.
03 / SOLUTIONS
Biome AI develops technology to improve human health through modulating the microbiome. Unlike the genome, the microbiome can be tweaked to improve the individual's well-being. Modifications in diet, exercise and key supplements can change its composition for the better. We aim to provide tools to guide and facilitate these positive manipulations.
MEET BIOME AI
Biome AI harnesses recent advances in genomics and computational technologies to decipher the interconnections of the microbiome and human health. Our goal is to positively disrupt the healthcare industry by harnessing the power of the microbiome to improve human health. We develop innovative technology for humans to influence and enhance their microbiome health. Unlike the genome, where we currently have limited options for change, the microbiome is dynamic and presents fresh possibilities to change. Using state-of-the-art DNA sequencing and analysis to monitor the microbiome, humans may improve their health by influencing microbiome composition by modifying aspects of their lifestyle such as diet, exercise and key microbiome supplements.
We are passionate about solving the problem of chronic disease. These conditions impact lives and cost taxpayers and the health care system billions. The recent re-discovery of the microbiome and its vast influence on health creates innovative opportunities to overcome these challenges. The human microbiome is the community of microorganisms living inside and on you, such as bacteria, fungi and viruses. Central to several aspects of human health, some scientists even liken it to the discovery of a new human organ. The microorganisms making up the microbiome are linked to many diseases including obesity, depression, cancer, cardiovascular health and arthritis.
Biome AI is at the forefront of accelerating microbiome research. We aim to improve human health by applying next generation sequencing and machine learning technologies to decipher the interconnections of the microbiome and the human body. This scientific field is in its infancy and experiencing exponential growth. Every day, revolutionary new connections to diverse aspects of human health and all of biology are being discovered.
Dr.Francis Hornicek MD Phd
Co-founder & Scientific Advisory Board Member
Francis John Hornicek, M.D., Ph.D., is currently chair of the Department of Orthopaedic Surgery at UCLA and an outstanding clinician-scientist and educator. A world famous orthopaedic oncologist, Dr. Hornicek served as The Henry J. Mankin, M.D., Endowed Scholar, Chief of the Orthopaedic Oncology Service, Vice Chair for Biological Research, Supervisor of the Sarcoma Molecular Biology Laboratory, Director of the Stephan L. Harris Chordoma Center, and Co-Director of the Center for Sarcoma and Connective Tissue Oncology at the Massachusetts General Hospital; Co-Leader of the Dana Farber/Harvard Cancer Center Oncology Group; and Professor of Orthopaedic Surgery at the Harvard Medical School.
Jeremy Same co-founded Lux Group Limited in 2010. Mr. Same began his career as a credit trader at ANZ Investment Bank in 2002, then departed in late 2003. He co-founded Living Corporate Apartments and serves as its Director. He also serves as a Non-Executive Director of BigThanks.com.au and Sames.com.au. He was Founder and Managing Director of MyTable, an online takeaway ordering platform, before exiting the business in 2012 in a sale to EatNow, to create Australia’s fastest growing food ordering website. He serves as Executive Director of luxgroup.com.
Dr. Hamed Khalili MD MPH
Scientific Advisory Board
Dr. Khalili is a gastroenterologist at the Massachusetts General Hospital (MGH)-Crohn’s and Colitis Center and an Assistant Professor at Harvard Medical School. His clinical and research interests are in inflammatory bowel diseases including Crohn’s disease, ulcerative colitis, and microscopic colitis. Dr. Khalili also leads the fecal microbiota transplantation program at MGH gastroenterology unit. To date, his research has focused on understanding and defining environmental predictors on risk and progression of inflammatory bowel diseases. He has been the principle investigator of numerous grants from American Gastroenterological Association, Crohn’s and Colitis Foundation, and National Institute of Health.
Paul Dabrowa is an experienced banker, having worked in London for Morgan Stanley and Goldman Sachs. He co-founded a company commercialising circadian management technology originally developed for NASA. Paul specialises in financial analysis, marketing and management. A former EU Parliamentary candidate, he also produced factual television programs for a European national broadcaster. He has an interest in philanthropy and is on a number of boards.
Co-founder & Analyst
Stefan Halvorsen is a doctoral student in biological and biomedical sciences at Harvard Medical School and holds a Masters in Medical Science from Boston University. He previously finished his undergraduate degree in Biomedical Physics at Northeastern University. He has worked throughout his graduate studies in a Harvard and MGH research laboratory developing novel computational tools and generating/analyzing biological data. These computational tools were designed to interpret large biological data-sets describing how the products of genes change and interact to modify cell fate.
Dr. Slim Sassi Phd
Co-founder & Scientific Adviser
Slim Sassi, Ph.D. is currently a junior faculty member of Harvard Medical School and a researcher in the Massachusetts General Hospital. He has a background in computational molecular evolutionary genetics, biochemistry, molecular biology, cancer biology, biotechnology tool development, and biological therapeutics. As junior faculty in Harvard Medical School, he undertook several projects ranging from cancer biology to developing biological therapeutics. Gaining significant expertise in high-throughput sequencing (next-generation sequencing) as applied to various applications and developed methods in this field.